Cancer Immunotherapy Winter School

Cancer Immunotherapy Winter School

Jan. 17-21, 2023 | Austin, TX & Virtual

Tailored to early-to-mid career scientists and clinicians in the field of cancer immunotherapy working in academic, clinical, industry and government settings, this hybrid program provides the best in cancer immunotherapy education taught by leading experts in the field. Participants gain a deep understanding of the core principles of tumor immunology and cancer immunotherapy, and developing areas in the field including biomarker technology, validation and clinical integration, clinical trial design, data analysis and considerations for combination therapies. With separate tracks, including clinical and research, participants can tailor their experience by selecting the educational path most relevant to their learning goals.

Register Now

Thank You To Our Sponsors

The 2023 Cancer Immunotherapy Winter School is generously supported*, in part, by independent medical education grants from: AstraZeneca Pharmaceuticals LP, and Wilson Wolf.
*This listing of supporters is current as of 01/05/2023.

Registration & Venue Details

Register now for the Cancer Immunotherapy Winter School hybrid program, in-person, and virtually in Austin, TX from January 17-21, 2023.

If you have questions about this program, please contact education@sitcancer.org.

Register Now

Registration Rates

Early Registration Regular Registration Onsite Registration
Student Member $425 $625 $675
Student Non-Member $470 $670 $720
General Member $775 $975 $1,025
General Non-Member $950 $1,050 $1,200
Industry Member $1,750 $1,950 $2,000
Industry Non-Member $2,000 $2,200 $2,250

Important Dates

Early Registration Deadline
Monday, December 12, 2022 (11:59 p.m. PST)

Housing Deadline
Tuesday, December 13, 2022

Regular Registration Closes
Saturday, January 21, 2023 (11:59 p.m. PST)

Onsite Registration Closes
Saturday, January 21, 2023 (12:30 p.m. CST)

Venue Information

The University of Texas at Austin
AT&T Hotel and Conference Center
1900 University Avenue
Austin, TX 78705

Please reserve your hotel before Dec. 12.

Reserve your room

Vaccination & Mask Requirements

COVID-19 Measures
SITC’s Cancer Immunotherapy Winter School, our goal is to have a safe and meaningful in-person experience. We will be adhering to the local safety guidelines and regulations. In addition, SITC in-person meetings will have the following safety measures in place.

Vaccinations
Proof of vaccination for COVID-19 will be required for all in-person program attendees. “Vaccinated” means either two weeks have passed since receiving the second dose of an FDA- or WHO-authorized double-dose COVID-19 vaccine or two weeks have passed since receiving the one dose of an FDA- or WHO-authorized single-dose COVID-19 vaccine. Please note that booster shots are highly recommended for those who are eligible (unless you have tested positive for COVID-19 in the last three months), but are not required. SITC is currently exploring options for validating this information and will communicate that process when it is available.

Masking Guidelines
SITC strongly recommends masks to be worn indoors for attendees.

View Program Preview

SITC Winter School Preview with Program Advisor Catherine Bollard, MBChB, MD

Don't miss the 2023 SITC Cancer Immunotherapy Winter School from Jan. 17-21, 2023, in Austin, Texas or virtual. Through this hybrid program attendees will have access to the best in cancer immunotherapy education taught by leading experts in the field. This program will provide a deep understanding of the core principles of tumor immunology and cancer immunotherapy as well as develop areas in the field including biomarker technology, validation and clinical integration, clinical trial design, data analysis and considerations for combination therapies.

Program Organizers

Christian Capitini, MD

Christian Capitini, MD
University of Wisconsin-Madison

Justin Eyquem, PhD

Justin Eyquem, PhD
University of Pennsylvania

Daniel Powell, PhD

Daniel Powell Jr., PhD
University of Pennsylvania

Catherine Bollard, MBChB, MD

Program Advisor
Catherine Bollard, MBChB, MD
Children’s National Hospital

Program Faculty


  • Panagiotis Benos, PhD
    University of Florida
  • Lisa H. Butterfield, PhD
    University of California San Francisco
  • Deborah Collyar, BS
    Patient Advocates in Research
  • Tricia Cottrell, MD, PhD
    Queen's University
  • Greg Delgoffe, PhD
    University of Pittsburgh
  • Devaveena Dey, PhD
    U.S. Food and Drug Administration
  • Victor Engelhard, PhD
    University of Virginia School of Medicine
  • Maryland Franklin, PhD
    Labcorp
  • Elizabeth Garrett-Mayer, PhD
    American Society of Clinical Oncology
  • Sacha Gnjatic, PhD
    Icahn School of Medicine at Mount Sinai
  • Emmanuel Adu-Gyamfi, PhD
    U.S. Food and Drug Administration
  • Howard Kaufman, MD, FACS
    Ankyra Therapeutics and Massachusetts General Hospital
  • Dinesh Kumar, PhD
    Parker Institute for Cancer Immunotherapy
  • Lewis Lanier, PhD
    University of California San Francisco
  • Greg Delgoffe, PhD
    University of Pittsburgh
  • Michael Lotze, MD, FACS
    Nurix Therapeutics
  • Jan Joseph Melenhorst, PhD
    Cleveland Clinic
  • Taha Merghoub, PhD
    Weill Cornell Medicine
  • Michael Morse, MD
    Duke University Medical Center
  • Yana Najjar, MD
    University of Pittsburgh
  • Bradley Nelson, PhD
    BC Cancer Deeley Research
  • Robert Scharpf, PhD
    Johns Hopkins University
  • Nirali Shah, MD, MHSc
    National Institute of Health
  • Sumit Subudhi, MD, PhD
    The University of Texas MD Anderson Cancer Center
  • Ryan Sullivan, MD
    Harvard Medical School and Massachusetts General Hospital
  • Christopher Takimoto, MD, PhD
    IGM Biosciences
  • Irina Tiper, PhD
    U.S. Food and Drug Administration
  • Todd Triplett, PhD
    Dell Medical School at the University of Texas
  • Jennifer Wargo, MD, MMSc
    The University of Texas MD Anderson Cancer Center
  • Jianda Yuan, MD, PhD
    Merck Research Laboratories
  • Andrew Weinberg, PhD
    Earle A. Chiles Research

Program Details

Continuing Education Credits

Continuing Education Credits are available for the CIWS 2023 program. Click here for more information.

Networking Opportunities

Attendees will have opportunities to expand their professional network, developing new relationships with faculty and other thought leaders through small group breakout sessions and virtual networking features.

Target Audience

  • Early-to-mid career scientists in the field of cancer immunotherapy working in academic, clinical, industry and government settings
  • Individuals new to the field working in academic, clinical, industry and government settings

Learning Objectives

Upon completion of the Cancer Immunotherapy Winter School, participants are able to:

  • Describe the core principles of tumor immunology and cancer immunotherapy
  • Discuss recent advancements in drug and biomarker technologies and their clinical application
  • Explain appropriate clinical and/or preclinical trial data analysis methods and best practices in clinical and/or preclinical trial design

Travel Awards

To support young investigators and clinicians interested in attending the Cancer Immunotherapy Winter School, SITC is pleased to offer applications for travel awards.

The Cancer Immunotherapy Winter School Travel Awards are intended for individuals who will attend the program in person. The award amount, up to $1,000, will be reimbursed for eligible expenses associated with travel to attend the 2023 Cancer Immunotherapy Winter School program in person and/or registration for the Cancer Immunotherapy Winter School program.

Two of the five travel awards will be reserved for those who self-identify as individuals from underrepresented racial and ethnic groups in the Biomedical Sciences according to the NIH definition.The information collected in response to the self-identifying process will only be viewed by SITC staff and Cancer Immunotherapy Winter School program organizers.

View eligibility & criteriaView 2023 Winners

Program Statement on Diversity, Equity and Inclusion

The Society for Immunotherapy of Cancer (SITC) understands the value of diversity, equity and inclusion and is committed to closing gaps within all facets of the organization, as well as ones in the field of immuno-oncology and biomedical sciences. Since 2018, SITC has been proactively following the NIH Statement on Diversity for those in underrepresented Populations in the U.S. Biomedical Sciences across planning, solicitation and implementation of all programming, including SITC’s Cancer Immunotherapy Winter School. In 2021, SITC formed the Diversity, Equity  and Inclusion Task Force to ensure participation from nationally underrepresented racial and ethnic groups, individuals with disabilities, individuals from disadvantaged backgrounds and women from biomedical sciences throughout all society programs and initiatives.

Enduring Materials

Enduring materials are available as permitted by presenters from this past year's 2022 Cancer Immunotherapy Winter School. 

Program registrants receive complimentary access to on-demand content. 

Enduring materials are available for purchase for those who did not register to attend the program. A discount is available for SITC Members. Renew your dues or become a SITC member today.

View or Purchase CIWS 2022 Enduring Materials

Past Programs

2022 PROGRAM

2021 PROGRAM

2020 PROGRAM

2019 PROGRAM

Related Resources

SITC offers a variety of resources about tumor immunology and cancer immunotherapy. Explore the pages below to learn more.

Basic Cancer Immunotherapy Principles

Learn the fundamentals of cancer immunotherapy through a variety of SITC programs.

Explore Resources

Bioinformatics

Discover how SITC is leveraging bioinformatics to enhance cancer immunotherapy research and treatments.

Learn More

Biomarkers

SITC’s clinician resources includes programs on biomarkers in the field of immuno-oncology.

Read More

Clinical Data and Practical Considerations

Explore SITC's journal, the Journal for Immunotherapy of Cancer (JITC), and other clinical resources.


View More

Combination Therapies

Discover related SITC resources about Combination Therapies.

Explore Programs

Practical Application Resources

Explore SITC's resources to learn about disease specific treatment algorithms, identification and treatment of common irAEs and how to overcome challenges in the clinic.

Learn More

Professional Development

Discover related SITC resources about Professional Development.

Browse Programs